Keyphrases
Age at Diagnosis
12%
B Symptoms
12%
Body Mass Index
100%
Cox Analysis
25%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Disease-related
25%
Hazard Ratio
25%
Improved Survival
100%
Increased Body Mass Index
100%
Low Stage
12%
Lymphoma Diagnosis
12%
Malignancy
12%
Most Common Form
12%
Non-Hodgkin Lymphoma
25%
Normal Weight
12%
Obese Patients
37%
Obesity
12%
Overall Survival
25%
Overweight or Obesity
12%
Overweight Patient
25%
Patient-specific
12%
Prognostic Factors
12%
Reduced Mortality
12%
Retrospective Cohort
12%
Risk of Death
37%
Risk Reduction
12%
Rituximab Era
12%
United States Veterans
100%
Weight Loss
12%
Weighted Data
12%
Working Diagnosis
25%
Nursing and Health Professions
Body Mass
100%
Diffuse Large B Cell Lymphoma
100%
Diseases
33%
Hazard Ratio
22%
Nonhodgkin Lymphoma
22%
Obesity
55%
Overall Survival
22%
Rituximab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Diseases
60%
Nonhodgkin Lymphoma
40%
Obesity
100%
Overall Survival
40%
Rituximab
20%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Body Mass
100%
Overall Survival
22%
Rituximab
11%